Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

March 15, 2021

Study Completion Date

April 20, 2021

Conditions
Alzheimer DiseaseParkinson Disease
Interventions
DRUG

Metabolic Cofactor Supplementation

Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).

DRUG

Sorbitol

As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.

Trial Locations (2)

34214

Medipol University Hospital, Istanbul

07400

Alanya Alaaddin Keykubat University Hospital, Antalya

All Listed Sponsors
collaborator

ScandiBio Therapeutics AB

INDUSTRY

collaborator

Alanya Alaaddin Keykubat University

OTHER

collaborator

Sahlgrenska University Hospital

OTHER

collaborator

KTH Royal Institute of Technology

OTHER

lead

Istanbul Medipol University Hospital

OTHER

NCT04044131 - Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients | Biotech Hunter | Biotech Hunter